| The role of peroxisome proliferator-activated receptor γ in pancreatic β cell function and survival: therapeutic implications for the treatment of type 2 diabetes mellitus. | |
| | |
MedLine Citation:
|
PMID: 20977574 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The pathogenesis of type 2 diabetes mellitus involves both peripheral insulin resistance and dysfunctional insulin secretion from the pancreatic β cell. Currently, there is intense research focus on delineating the etiologies of pancreatic β cell dysfunction in type 2 diabetes. However, there remains an unmet clinical need to establish therapeutic guidelines and strategies that emphasize the preservation of pancreatic β cell function in at-risk and affected individuals. Thiazolidinediones are orally active agents approved for use in type 2 diabetes and act as agonists of the nuclear hormone receptor PPAR-γ. These drugs improve insulin sensitivity, but there is also a growing appreciation of PPAR-γ actions within the β cell. PPAR-γ has been shown to regulate directly key β cell genes involved in glucose sensing, insulin secretion and insulin gene transcription. Further, pharmacologic PPAR-γ activation has been shown to protect against glucose-, lipid-, cytokine- and islet amyloid polypeptide (IAPP)-induced activation of numerous stress pathways. This article will review the mechanisms by which PPAR-γ activation acts to maintain β cell function and survival in type 2 diabetes mellitus and highlight some of the current controversies in this field. |
| | |
Authors:
|
D Gupta; T Kono; C Evans-Molina |
Related Documents
:
|
2935694 - Beta-endorphin concentrations in the hypothalamus, pituitary and plasma of streptozotoc... 20356834 - The mitochondrial 2-oxoglutarate carrier is part of a metabolic pathway that mediates g... 18621094 - Impact of metabolic abnormalities for beta cell function: clinical significance and und... 18426794 - The rala gtpase is a central regulator of insulin exocytosis from pancreatic islet beta... 3911734 - Kinetic models for plasma disappearance of insulin in normal subjects. 3810694 - Parameters of altered plasma glucose levels during short intervals in diabetic patients. |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural |
Journal Detail:
|
Title: Diabetes, obesity & metabolism Volume: 12 ISSN: 1463-1326 ISO Abbreviation: Diabetes Obes Metab Publication Date: 2010 Dec |
Date Detail:
|
Created Date: 2010-10-27 Completed Date: 2011-06-03 Revised Date: 2011-08-01 |
Medline Journal Info:
|
Nlm Unique ID: 100883645 Medline TA: Diabetes Obes Metab Country: England |
Other Details:
|
Languages: eng Pagination: 1036-47 Citation Subset: IM |
Copyright Information:
|
© 2010 Blackwell Publishing Ltd. |
Affiliation:
|
Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Diabetes Mellitus, Type 2
/
drug therapy*,
metabolism,
physiopathology Female Humans Insulin-Secreting Cells / metabolism* Male PPAR gamma / metabolism*, physiology Practice Guidelines as Topic Thiazolidinediones / metabolism* |
| Grant Support | |
ID/Acronym/Agency:
|
K08 DK080225/DK/NIDDK NIH HHS; K08 DK080225-06/DK/NIDDK NIH HHS; R03 DK 089147/DK/NIDDK NIH HHS; R03 DK089147-02/DK/NIDDK NIH HHS; T32 HL079995/HL/NHLBI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/PPAR gamma; 0/Thiazolidinediones |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Cardiovascular risk and thiazolidinediones--what do meta-analyses really tell us?
Next Document: Bromocriptine: old drug, new formulation and new indication.